{"id":"immunotherapy-monotherapy","safety":{"commonSideEffects":[{"rate":"3-4%","effect":"Pneumonitis"},{"rate":"1-2%","effect":"Colitis"},{"rate":"1%","effect":"Hypophysitis"},{"rate":"10-20%","effect":"Arthralgia"},{"rate":"20-30%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This class of drugs works by blocking the interaction between PD-1 and PD-L1, allowing the immune system to attack cancer cells more effectively.","oneSentence":"Immune checkpoint inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:51:01.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT06888323","phase":"PHASE1","title":"Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-27","conditions":"Refractory Myelodysplastic Syndrome","enrollment":30},{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":"Advanced Biliary Tract Carcinoma","enrollment":75},{"nctId":"NCT04432207","phase":"PHASE1","title":"A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2020-11-30","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":24},{"nctId":"NCT07489066","phase":"PHASE2","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-01","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)","enrollment":120},{"nctId":"NCT07392957","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-04-30","conditions":"Glioblastoma","enrollment":54},{"nctId":"NCT07483112","phase":"NA","title":"Fiber-Boost Randomized Controlled Trial","status":"RECRUITING","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2025-10-07","conditions":"Non-Small Cell Carcinoma of Lung","enrollment":42},{"nctId":"NCT05635643","phase":"PHASE1","title":"Study of CHS-114 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2022-12-15","conditions":"Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT06108479","phase":"PHASE1","title":"Study of DF6215 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2023-11-28","conditions":"Solid Tumor, Adult, Solid Tumor Cancer","enrollment":35},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT07161414","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-25","conditions":"Advanced Solid Tumors","enrollment":40},{"nctId":"NCT07403136","phase":"PHASE2","title":"Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT04943848","phase":"PHASE1","title":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2022-01-10","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":36},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07297212","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-01-15","conditions":"Recurrent Glioblastoma","enrollment":75},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT07280741","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-02","conditions":"Autoimmune Rheumatic Diseases","enrollment":200},{"nctId":"NCT07000149","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma","enrollment":1116},{"nctId":"NCT06957418","phase":"PHASE2","title":"Alzheimer's Tau Platform: Master Protocol","status":"NOT_YET_RECRUITING","sponsor":"Paul S. Aisen","startDate":"2026-06-30","conditions":"Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease","enrollment":750},{"nctId":"NCT06488482","phase":"PHASE3","title":"Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-12-19","conditions":"High-risk Melanoma","enrollment":1792},{"nctId":"NCT06063317","phase":"PHASE1","title":"A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2023-10-02","conditions":"Solid Tumor, Adult","enrollment":25},{"nctId":"NCT04221542","phase":"PHASE1","title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Amgen","startDate":"2020-03-04","conditions":"Prostate Cancer","enrollment":479},{"nctId":"NCT04695327","phase":"PHASE1","title":"TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy","status":"COMPLETED","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2021-01-11","conditions":"Solid Tumor","enrollment":32},{"nctId":"NCT07205731","phase":"PHASE2","title":"Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-10-07","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":95},{"nctId":"NCT05721755","phase":"PHASE3","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-06-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT06759649","phase":"PHASE1","title":"A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Compugen Ltd","startDate":"2025-01-07","conditions":"Neoplasm, Cancer, Malignant Tumors","enrollment":200},{"nctId":"NCT01909453","phase":"PHASE3","title":"Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-12","conditions":"Melanoma","enrollment":921},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT07441174","phase":"PHASE1, PHASE2","title":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2026-02-28","conditions":"Solid Tumor Cancer, PDAC","enrollment":92},{"nctId":"NCT04735978","phase":"PHASE1","title":"Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"Replimune Inc.","startDate":"2020-12-29","conditions":"Advanced Solid Tumor","enrollment":123},{"nctId":"NCT03564197","phase":"NA","title":"18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-10-25","conditions":"NSCLC Stage IV","enrollment":80},{"nctId":"NCT05549297","phase":"PHASE3","title":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","status":"RECRUITING","sponsor":"Immunocore Ltd","startDate":"2022-12-19","conditions":"Advanced Melanoma","enrollment":540},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT04526730","phase":"PHASE2","title":"Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-22","conditions":"Melanoma","enrollment":17},{"nctId":"NCT04751929","phase":"PHASE2","title":"Abemaciclib With or Without Atezolizumab for mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-08-20","conditions":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":19},{"nctId":"NCT07422779","phase":"NA","title":"Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-03-01","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":100},{"nctId":"NCT05396833","phase":"PHASE1","title":"Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-06-07","conditions":"Metastatic or Locally Advanced Unresectable Solid Tumors","enrollment":120},{"nctId":"NCT06450106","phase":"PHASE1","title":"Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy","status":"RECRUITING","sponsor":"SURGE Therapeutics","startDate":"2025-05-08","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT05710848","phase":"PHASE1, PHASE2","title":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","status":"RECRUITING","sponsor":"SURGE Therapeutics","startDate":"2023-07-11","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":75},{"nctId":"NCT05233436","phase":"PHASE1","title":"PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-02-24","conditions":"Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":21},{"nctId":"NCT05267626","phase":"PHASE1, PHASE2","title":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer","status":"RECRUITING","sponsor":"Aulos Bioscience, Inc.","startDate":"2022-04-04","conditions":"Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma","enrollment":159},{"nctId":"NCT05775159","phase":"PHASE2","title":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-24","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":294},{"nctId":"NCT06300411","phase":"PHASE1","title":"SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"SURGE Therapeutics","startDate":"2024-07-29","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT02519348","phase":"PHASE2","title":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2015-10-19","conditions":"Hepatocellular Carcinoma","enrollment":433},{"nctId":"NCT07293754","phase":"PHASE1, PHASE2","title":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Repertoire Immune Medicines","startDate":"2025-12-12","conditions":"Advanced Malignant Solid Tumor","enrollment":150},{"nctId":"NCT02158091","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-06-27","conditions":"Chronic Lymphocytic Leukemia","enrollment":32},{"nctId":"NCT07408063","phase":"PHASE2","title":"A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-02-02","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07403877","phase":"PHASE2","title":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Colorectal Cancer (MSI-H)","enrollment":114},{"nctId":"NCT06750185","phase":"PHASE1","title":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-01-13","conditions":"Advanced Solid Tumor","enrollment":39},{"nctId":"NCT03516708","phase":"PHASE1, PHASE2","title":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-06","conditions":"Rectal Cancer","enrollment":49},{"nctId":"NCT07360743","phase":"PHASE2","title":"Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-04","conditions":"Non Small Cell Lung Cancer (Squamous or Non Squamous)","enrollment":275},{"nctId":"NCT05577702","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2023-03-08","conditions":"Non Small Cell Lung Cancer","enrollment":121},{"nctId":"NCT04884282","phase":"PHASE2","title":"Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2021-10-12","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":105},{"nctId":"NCT05236114","phase":"","title":"GEMINI-NSCLC: NSCLC Biomarker Study","status":"RECRUITING","sponsor":"Tempus AI","startDate":"2022-06-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1200},{"nctId":"NCT05415358","phase":"","title":"Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-01-17","conditions":"Lung Cancer, Nonsmall Cell","enrollment":23},{"nctId":"NCT06469281","phase":"PHASE1","title":"A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-06","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer","enrollment":90},{"nctId":"NCT05929235","phase":"PHASE1","title":"A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Flare Therapeutics Inc.","startDate":"2023-08-24","conditions":"Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label","enrollment":120},{"nctId":"NCT04669171","phase":"PHASE1, PHASE2","title":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Enterome","startDate":"2021-07-05","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":80},{"nctId":"NCT04260529","phase":"PHASE1, PHASE2","title":"CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations","status":"COMPLETED","sponsor":"Cytovation AS","startDate":"2020-04-30","conditions":"Advanced Solid Tumor Malignancy","enrollment":60},{"nctId":"NCT07376512","phase":"","title":"Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis","status":"NOT_YET_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2026-03-01","conditions":"Non-Small Cell Lung Cancer, Melanoma (Skin Cancer)","enrollment":378},{"nctId":"NCT07371611","phase":"PHASE3","title":"Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Qunxing Li,MD","startDate":"2026-01-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)","enrollment":104},{"nctId":"NCT04028063","phase":"PHASE2","title":"Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-01-28","conditions":"Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma","enrollment":65},{"nctId":"NCT03333616","phase":"PHASE2","title":"Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-12-28","conditions":"Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder","enrollment":100},{"nctId":"NCT02408861","phase":"PHASE1","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-10-21","conditions":"Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection","enrollment":79},{"nctId":"NCT03891953","phase":"PHASE1","title":"Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma","enrollment":98},{"nctId":"NCT03994601","phase":"PHASE1, PHASE2","title":"An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-09-06","conditions":"Advanced Cancer","enrollment":219},{"nctId":"NCT07349836","phase":"EARLY_PHASE1","title":"Application of mRNA Immunotherapy Technology in EB Virus Related Diseases","status":"NOT_YET_RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2026-01-10","conditions":"EBV-associated Tumors","enrollment":40},{"nctId":"NCT03313206","phase":"PHASE2","title":"Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-05-28","conditions":"Head and Neck Mucosal Melanomas","enrollment":60},{"nctId":"NCT06974110","phase":"PHASE1","title":"Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"MOMA Therapeutics","startDate":"2025-07-16","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer","enrollment":132},{"nctId":"NCT05529316","phase":"PHASE2","title":"A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agenus Inc.","startDate":"2022-12-12","conditions":"Advanced Melanoma","enrollment":150},{"nctId":"NCT05651022","phase":"PHASE1, PHASE2","title":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Indaptus Therapeutics, Inc","startDate":"2023-02-28","conditions":"Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)","enrollment":120},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT06062420","phase":"PHASE2","title":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-11-14","conditions":"Neoplasms, Head and Neck","enrollment":316},{"nctId":"NCT07329907","phase":"PHASE2","title":"Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-12-01","conditions":"Warts, Human Papilloma Virus (HPV)","enrollment":126},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT05002569","phase":"PHASE3","title":"A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2021-10-19","conditions":"Melanoma","enrollment":1093},{"nctId":"NCT05565378","phase":"PHASE2","title":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Lung Cancer, Non-Small Cell","enrollment":351},{"nctId":"NCT05544929","phase":"PHASE1","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-10-26","conditions":"Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell","enrollment":126},{"nctId":"NCT06547736","phase":"PHASE2","title":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-14","conditions":"Pancreatic Cancer","enrollment":160},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT07300891","phase":"PHASE2","title":"T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2026-01-31","conditions":"Refractory Solid Cancer Patients Unexposed to Immunotherapy","enrollment":72},{"nctId":"NCT04847466","phase":"PHASE2","title":"Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-14","conditions":"Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC","enrollment":18},{"nctId":"NCT06022029","phase":"PHASE1","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","status":"RECRUITING","sponsor":"OncoNano Medicine, Inc.","startDate":"2023-10-13","conditions":"Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma","enrollment":168},{"nctId":"NCT03161431","phase":"PHASE1","title":"SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syntrix Biosystems, Inc.","startDate":"2019-06-12","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":77},{"nctId":"NCT07293468","phase":"PHASE2, PHASE3","title":"Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)","status":"RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2024-04-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":106},{"nctId":"NCT05860296","phase":"PHASE1, PHASE2","title":"Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","status":"TERMINATED","sponsor":"SignalChem Lifesciences Corporation","startDate":"2023-05-31","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic","enrollment":36},{"nctId":"NCT05856981","phase":"PHASE1","title":"Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sairopa B.V.","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer","enrollment":130},{"nctId":"NCT07289048","phase":"PHASE2","title":"A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-12-20","conditions":"SCLC,Extensive Stage","enrollment":35},{"nctId":"NCT07285850","phase":"PHASE2, PHASE3","title":"The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD","status":"RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2025-10-20","conditions":"HCC - Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT05733598","phase":"PHASE2","title":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT04009681","phase":"PHASE1, PHASE2","title":"A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)","status":"TERMINATED","sponsor":"Synthorx, Inc, a Sanofi company","startDate":"2019-06-20","conditions":"Metastasis","enrollment":175},{"nctId":"NCT06794775","phase":"PHASE3","title":"SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma","status":"RECRUITING","sponsor":"Hildur Helgadottir","startDate":"2025-07-10","conditions":"Malignant Melanoma Stage III","enrollment":128},{"nctId":"NCT05522660","phase":"PHASE3","title":"Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2022-11-30","conditions":"Non-Small Cell Lung Cancer, Melanoma","enrollment":180},{"nctId":"NCT06790966","phase":"PHASE3","title":"Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PDS Biotechnology Corp.","startDate":"2025-05-30","conditions":"Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":351},{"nctId":"NCT03556228","phase":"PHASE1, PHASE2","title":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","status":"RECRUITING","sponsor":"VM Oncology, LLC","startDate":"2018-06-08","conditions":"Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer","enrollment":242},{"nctId":"NCT07274384","phase":"PHASE2","title":"Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial","status":"NOT_YET_RECRUITING","sponsor":"Università Vita-Salute San Raffaele","startDate":"2026-01-01","conditions":"NSCLC (Non-small Cell Lung Cancer), Hyperprogression","enrollment":74},{"nctId":"NCT02374242","phase":"PHASE2","title":"Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2014-11-04","conditions":"Melanoma, Brain Metastases","enrollment":76},{"nctId":"NCT04430452","phase":"PHASE2","title":"Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Mary Feng, MD","startDate":"2022-02-04","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Immunotherapy monotherapy","genericName":"Immunotherapy monotherapy","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Biologic","firstApprovalDate":"","aiSummary":"Immune checkpoint inhibitor Used for Non-small cell lung cancer, Melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}